RainDance Technologies opens patent suit against 10X Genomics

RainDance Technologies has opened a patent infringement case against 10X Genomics. The suit alleges that 10X Genomics--which exited stealth mode and raised $55.5 million last month--is using tech protected by patents licensed to RainDance from the University of Chicago. 10X Genomics has hit back against the claims. "We are firmly of the view that our products do not infringe any claims of any of the asserted patents," CEO Serge Saxonov said in a statement. Release | More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.